Literature DB >> 23040628

The presence of detrusor muscle in the pathological specimen after transurethral resection of primary pT1 bladder tumors and its relationship to operator experience.

Morgan Rouprêt1, David R Yates, Justine Varinot, Véronique Phé, Emmanuel Chartier-Kastler, Marc-Olivier Bitker, Eva Compérat.   

Abstract

INTRODUCTION: To assess the quality of transurethral resection of bladder tumors (TURBTs) performed by "senior" and "junior" urologists for pT1 tumors in terms of detrusor muscle (DM) presence and recurrence rate at 3 month first cystoscopy (RR-FC). Non-muscle invasive bladder cancer (NMIBC) is a heterogeneous group with differing biological potentials. Tumors invading lamina propria (pT1) have an increased propensity for recurrence and progression. Accurate staging at the time of primary TURBT, including the presence of DM, is crucial to avoid understaging and unnecessary delay in definitive treatment.
MATERIALS AND METHODS: We analyzed our maintained bladder tumor database (TURBTs from 2002 to 2009) and selected patients diagnosed with pT1 bladder tumors. Data on surgeon status, tumor characteristics (size, TNM stage 2009, grade, DM presence) and RR-FC were retrieved. Surgeons were stratified into "senior" and "junior" according to the years of prior training.
RESULTS: Of the 340 TURBTs for pT1 tumors, "senior" and "junior" surgeons performed 237 (69.7%) and 103 (30.3%), respectively. Overall, 238 (70%) TURBTs had DM in the specimen, including 175 (73.8%) and 63 (61.3%) for the "senior" and "junior" operators, respectively (p = 0.02). The overall RR-FC was 37.4% (n = 127) and was significantly different for DM presence and DM absence (30.7% versus 52.9%; p = 0.01). On multivariate analysis, tumor recurrence was associated with "junior" operator experience independent of the presence or absence of DM (OR = 2.33 [1.45-3.74]) p = 0.01).
CONCLUSIONS: The presence of DM in a primary TURBT for pT1 NMIBC is directly associated with operator experience, with an associated increased 3 month recurrence rate for "junior" resectionists.

Entities:  

Mesh:

Year:  2012        PMID: 23040628

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  7 in total

1.  Role of surgeon experience in the outcome of transurethral resection of bladder tumors.

Authors:  Mohamed Hassan Ali; Ahmed Eltobgy; Iman Yehia Ismail; Ammar Ghobish
Journal:  Urol Ann       Date:  2020-10-15

2.  Surgeon has a major impact on long-term recurrence risk in patients with non-muscle invasive bladder cancer.

Authors:  Alexander Rolevich; Alexander Minich; Tatiana Nabebina; Sergey Polyakov; Sergey Krasny; Oleg Sukonko
Journal:  Cent European J Urol       Date:  2016-04-19

3.  Differences in Pathologic Results of Repeat Transurethral Resection of Bladder Tumor (TURBT) according to Institution Performing the Initial TURBT: Comparative Analyses between Referred and Nonreferred Group.

Authors:  Hyeong Dong Yuk; Jung Kwon Kim; Chang Wook Jeong; Cheol Kwak; Hyeon Hoe Kim; Ja Hyeon Ku
Journal:  Biomed Res Int       Date:  2018-09-06       Impact factor: 3.411

Review 4.  Transurethral resection of bladder tumour (TURBT).

Authors:  Lawrence H C Kim; Manish I Patel
Journal:  Transl Androl Urol       Date:  2020-12

5.  Risk Stratification for the Rate and Location of Residual Bladder Tumor for the Decision of Re-Transurethral Resection of Bladder Tumor.

Authors:  Junjie Fan; Xing Zhang; Jinhai Fan; Lei Li; Dalin He; Kaijie Wu
Journal:  Front Oncol       Date:  2022-01-27       Impact factor: 6.244

Review 6.  Non-Muscular Invasive Bladder Cancer: Re-envisioning Therapeutic Journey from Traditional to Regenerative Interventions.

Authors:  Kuan-Wei Shih; Wei-Chieh Chen; Ching-Hsin Chang; Ting-En Tai; Jeng-Cheng Wu; Andy C Huang; Ming-Che Liu
Journal:  Aging Dis       Date:  2021-06-01       Impact factor: 6.745

7.  Prediction of the risk of surgical complications in patients undergoing monopolar transurethral resection of bladder tumour - a prospective multicentre observational study.

Authors:  Sławomir Poletajew; Wojciech Krajewski; Dominika Gajewska; Joanna Sondka-Migdalska; Michał Borowik; Paweł Buraczyński; Mateusz Dzięgała; Marcin Łykowski; Maciej Przudzik; Andrzej Tukiendorf; Rafał Woźniak; Krzysztof Bar; Zbigniew Jabłonowski; Marek Roslan; Marcin Słojewski; Romuald Zdrojowy; Piotr Radziszewski; Konrad Dziobek
Journal:  Arch Med Sci       Date:  2019-10-07       Impact factor: 3.318

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.